Clinical efficacy of montelukast sodium combined with procaterol hydrochloride in treating refractory mycoplasma pneumonia in children and its effects on lung function and serum inflammatory factor levels
Objective To observe the clinical effect of montelukast sodium combined with propacaterol hydrochloride in the treatment of refractory mycoplasma pneumonia in children and its effect on lung function and serum inflammatory factor level.Methods Eighty-two children who attended the Eighth People's Hospital of Hefei City from June 2021 to May 2023 were selected and randomly divided into a study group(42 cases)and a control group(40 cases).The study group was treated with montelukast sodium(oral,five mg once daily for age ≥ six years and four mg once daily for age＜six years)on top of the control group.Both groups were treated for 14 d.The treatment effect,recovery time,lung function indexes and serum inflammatory factor levels before and after treatment were compared,and the occurrence of adverse reactions was recorded.Results The total effective rate of the study group(95.24％)was significantly higher than that of the control group(72.50％,P＜0.05).The study group's hospitalization time,fever reduction time,cough suppression time,asthma disappearance time,rales disappearance time and lung shadow disappearance time were significantly lower than those of the control group(P＜0.05).Compared with the pre-treatment period,the one-second expiratory volume(FEV1),expiratory lung capacity(FVC),maximal mid-expiratory flow(MMEF),maximal peak expiratory flow rate(PEF),and FEV1/FVC were significantly higher in the two study groups after 14 d of treatment(P＜0.05);serum interleukin-6(IL-6),interleukin-13(IL-13),interleukin-17(IL-17),tumor necrosis factor-α(TNF-α),γ-interferon(IFN-γ),C-reactive protein(CRP)and procalcitonin(PCT)levels were significantly reduced(P＜0.05).And the FEV1,FVC,MMEF,PEF and FEV1/FVC of the study group were significantly higher than those of the control group after treatment(P＜0.05);serum IL-6,IL-13,IL-17,IFN-γ,TNF-α,CRP and PCT levels were significantly lower than those of the control group(P＜0.05).The difference in the incidence of adverse reactions between the two groups was not statistically significant.Conclusion The effect of montelukast sodium combined with procaterol hydrochloride in the treatment of refractory mycoplasma pneumonia in children is better,which can effectively improve the lung function indexes of the children,reduce the level of serum inflammatory factors,and has higher safety.
children with refractory mycoplasma pneumoniae pneumoniamonelukast sodiumprocaterol hydrochloridelung functioninflammatory factors
NETL
NSTL
万方数据
